Navigation Links
LABS Inc. Adds Life Sciences Industry Veteran Kevin M. Smith to Board of Directors
Date:12/7/2010

CENTENNIAL, Colo., Dec. 7, 2010 /PRNewswire/ -- LABS Inc., the premier transplant reference and consultative laboratory in the country, today announced that Kevin M. Smith, Chief Operating Officer of the Colorado Institute for Drug, Device and Diagnostic Development (CID4), has joined the company's Board of Directors.  Smith brings a wealth of experience running businesses in the biosciences industries.

In addition to his current role as COO of CID4, Smith was a member of the group that developed the original business plan and state grant proposal for the organization. He also sits on the boards of Sophono, Inc.; PeptiVir, Inc., and participates on the Centura Audit and Corporate Responsibility Management Committee.

Prior to CID4, Smith was Managing Director of Act Three Consulting, LLC, which provided consulting services to management teams and their advisors during times of dramatic change.  Before founding Act Three, Smith spent nine years as President of Gambro, Inc., the US holding company for the publicly-traded, Swedish-based Gambro Group.  The US operations of Gambro included the manufacture and distribution of cardiovascular, blood separation and renal dialysis products and the operation of US and international kidney dialysis centers. Before joining Gambro, Smith was an audit partner in the Denver and New York offices of Ernst & Young, where he specialized in entrepreneurial services and led the formation of E&Y's Denver Life Sciences Practice.

"We are honored to have Kevin join our Board of Directors at this critical time in LABS Inc.'s growth," said Elizabeth Hearty, Chief Executive Officer of LABS Inc. "His personal connection to the transplant community and his experience driving strategic growth initiatives for bioscience companies will be a valuable addition to our already accomplished Board."

"I welcome the chance to work with the LABS Inc. team to forward its mission and capitalize on opportunities to further the success of the organization," said Smith.

LABS Inc. has been serving the transplant community for nearly 30 years in the areas of infectious disease, immunogenetics and microbiology, bringing unparalleled consultative and regulatory expertise to its customers. In 2009, LABS Inc. brought its expertise to blood collection programs nationwide and now offers a complete testing menu to its blood services clients. LABS Inc.'s proven ability to manage partnerships and transport samples effectively and efficiently with timely result reporting provides the blood services community with an alternative resource for all testing needs.

About LABS Inc.

LABS Inc. is a premier transplant medicine reference laboratory bringing unparalleled consultative expertise and industry knowledge to its clients. Testing is focused on donor eligibility determination and final product safety; infectious disease testing, microbiology, histocompatibilty and environmental monitoring. LABS Inc. is committed to respectfully fulfilling the wishes of donors by ensuring the gift is able to generate positive patient outcomes. LABS Inc. employs over 100 people. The company is located in Centennial, CO with satellite facilities in St. Louis, MO and Philadelphia, PA.


'/>"/>
SOURCE LABS Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):